HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PIII
P3 Health Partners Inc.
PIII lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PIII Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
PIII's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PIII PE Valuation
PIII has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PIII Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| -- |
Analysts expect PIII's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PIII Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$33.06 | +$17.95 |
| Q1 2026 | -$38.66 | +$13.62 |
| Q4 2025 | -$45.26 | +$8.74 |
| Q3 2025 | -$45.18 | -$4.18 |
| Q2 2025 | -$51.01 | -$19.51 |
| Q1 2025 | -$52.28 | -$23.78 |
| Q4 2024 | -$54.00 | -$22.50 |
| Q3 2024 | -$41.00 | +$93.00 |
PIII is still losing money, but far less than before: $33.06 per share over the past year, against $134.00 at its worst in late 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PIII on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PIII Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $396.3M | +15% |
| Q2 2026 | $386.4M | +8.6% |
| Q1 2026 | $386.4M | +3.5% |
| Q4 2025 | $384.8M | +3.8% |
| Q3 2025 | $345.3M | -4.7% |
| Q2 2025 | $355.8M | -6.2% |
| Q1 2025 | $373.2M | -3.9% |
| Q4 2024 | $370.7M | +6.9% |
PIII's revenue has grown year over year for four quarters in a row: $396M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +19 points |
| Q2 2026 | 11% | +20 points |
| Q1 2026 | 2.1% | +12 points |
| Q4 2025 | -40% | -2.6 points |
| Q3 2025 | -13% | +17 points |
| Q2 2025 | -9.6% | -1.3 points |
| Q1 2025 | -10% | +1.1 points |
| Q4 2024 | -37% | -19 points |
PIII has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
PIII has the stronger cash trend. Its trailing FCF is down 6.5% versus its history, compared with HIMS at down 84%.
PIII Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$61.9M | -$45.3M |
| Q1 2026 | -$27.5M | +$6M |
| Q4 2025 | -$25.7M | +$31.5M |
| Q2 2025 | -$16.6M | -$6.4M |
| Q1 2025 | -$33.5M | -$13.4M |
| Q4 2024 | -$57.2M | -$41.6M |
| Q3 2024 | -$22.6M | -$14.6M |
| Q2 2024 | -$10.2M | +$19.8M |
PIII has burned cash in almost every quarter: −$116M over the past year, against −$130M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PIII on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PIII Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +97% | +3.3M shares |
| 1 year | +103% | +3.4M shares |
| 3 years | +6% | +373K shares |
PIII has 7M diluted shares, up 103% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $180,000 |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PIII Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 28.6x | High |
PIII's net debt is more than 20 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PIII Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 2.8 | Oversold |
PIII's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PIII PE vs Healthcare Sector
PIII has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PIII Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.68 | 41% below |
| 20 week MA | $7.81 | 65% below |
| 50 week MA | $6.16 | 55% below |
| 100 week MA | $7.25 | 62% below |
| 200 week MA | $34.7 | 92% below |
PIII is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PIII Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $488.5 | $363.0 | -26% |
| 2022 | $363.0 | $101.5 | -72% |
| 2023 | $101.5 | $70.5 | -31% |
| 2024 | $70.5 | $10.0 | -86% |
| 2025 | $10.0 | $3.57 | -64% |
| 2026 YTD | $3.57 | $2.75 | -23% |
PIII has the edge over HIMS on returns for 2026, with the stronger performance.